2013
Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy
Karim SP, Adelman RA. Profile of verteporfin and its potential for the treatment of central serous chorioretinopathy. Clinical Ophthalmology 2013, Volume 7: 1867-1875. PMID: 24092965, PMCID: PMC3788817, DOI: 10.2147/opth.s32177.Peer-Reviewed Original ResearchCentral serous chorioretinopathySerous chorioretinopathyAnti-vascular endothelial growth factor agentsEndothelial growth factor agentsSafety of PDTTreatment of CSCRPhotodynamic therapyChronic recurrent formGrowth factor agentsPermanent visual lossPossible pathophysiologic mechanismsSerous retinal detachmentProspective interventional studyLong-term efficacyPigment epithelial detachmentPotential therapeutic optionEfficacy of PDTMajority of casesFactor agentsAnatomic improvementFoveal atrophyPigment epitheliopathyRetinal detachmentVisual lossFluorescein angiography
2009
Factor VII–Verteporfin for Targeted Photodynamic Therapy in a Rat Model of Choroidal Neovascularization
Lu F, Hu Z, Sinard J, Garen A, Adelman RA. Factor VII–Verteporfin for Targeted Photodynamic Therapy in a Rat Model of Choroidal Neovascularization. Investigative Ophthalmology & Visual Science 2009, 50: 3890-3896. PMID: 19357351, DOI: 10.1167/iovs.08-2833.Peer-Reviewed Original ResearchConceptsVisudyne photodynamic therapyChoroidal neovascularizationCNV lesionsTargeted photodynamic therapyDay 7Rat modelSafety of PDTPhotodynamic therapyOcular side effectsBrown Norway ratsFrequency of leakageFluorescein angiographyEfficacious doseHistopathologic evaluationLaser photocoagulationSide effectsFactor VIIDay 14LesionsNormal vasculatureRatsEndothelial cellsTherapyDoseNeovascularization